Loading

GOVERNMENT

  • by Paul Armentano, NORML Deputy Director May 20, 2014

    South Carolina lawmakers have approved legislation, Senate Bill 839, reclassifying varieties of cannabis possessing minute quantities of THC as an industrial crop rather than a controlled substance. The measure states, “It is lawful for an individual to cultivate, produce, or otherwise grow industrial hemp in this State to be used for any lawful purpose, including, but not limited to, the manufacture of industrial hemp products, and scientific, agricultural, or other research related to other lawful applications for industrial hemp.”

    Members of the Senate voted 42 to zero in favor of the bill. House members late last week also approved the measure by a vote of 72 to 28. Senate Bill 839 now awaits action by Republican Governor Nikki Haley.

    In February, members of Congress approved language (Section 7606) in the omnibus federal Farm Bill (aka the United States Agricultural Act of 2014) authorizing states to sponsor hemp research absent federal reclassification of the plant. Since that time, lawmakers in five states — Hawaii, Indiana, Nebraska, Tennessee, and Utah — have enacted legislation allowing for state-sponsored hemp cultivation.

    On Monday, Illinois Senate members unanimously approved similar legislation, House Bill 5085, in their state. Members of the House had previously voted 70 to 28 in favor of an earlier version of the bill. Once both chambers agree to concurrent language, the measure will go to the Governor’s desk.

    In total, more than a dozen states have enacted legislation redefining hemp as an agricultural commodity and allowing for state-sponsored research and/or cultivation of the crop.

    Last week, Kentucky state officials sued the US Drug Enforcement Administration after the agency refused to turn over a shipment of hemp seeds that were intended to be used as part of a state-approved research program. State officials designed the program to be compliant with Section 7606 of the federal farm bill. A federal hearing in the matter is scheduled for Wednesday, May 21.

    According to the U.S. Congressional Resource Service, the United States is the only developed nation that fails to cultivate industrial hemp as an economic crop.

  • by Paul Armentano, NORML Deputy Director May 19, 2014

    Minnesota House and Senate lawmakers, along with Democrat Gov. Mark Dayton, agreed late last week to legislation that seeks to provide access to limited preparations of cannabis to qualified patients.

    The finalized language represents a compromise between dueling House (House File 1818) and Senate bills (Senate File 1641), both of which had passed their respective chambers. On Friday afternoon, House lawmakers approved the compromised bill by a vote of 89 to 40. Members of the Senate voted 46 to 16 for the amended measure, sending it to the Governor’s desk. 

    Under the plan, state regulators intend to license two producers of cannabis and up to eight distribution centers. To be eligible to participate in the state’s program, patients need to possess a physician’s recommendation and be diagnosed with one of eight qualifying conditions (cancer/cachexia, glaucoma, HIV/AIDS, Tourette’s Syndrome, Amyotrophic Lateral Sclerosis, seizures — including those characteristic of epilepsy, severe and persistent muscle spasms — including those characteristic of multiple sclerosis, and/or Crohn’s Disease) and/or a terminal illness, and be registered with the state Department of Health.

    Unlike other state medical cannabis programs, the Minnesota plan does not permit qualified patients to possess or obtain whole-plant cannabis. Instead, the forthcoming law mandates that state-licensed distribution centers provide oils, pills, and/or extracts prepared from the plant. Such products would be subject to laboratory testing for purity and potency. Patients’ health care provider must compile ongoing reports in regards to their patients’ progress.

    Cannabis-based preparations are expected to be available to qualified patients by no later than July 1, 2015. Additional details on the forthcoming program are available here.

  • by Erik Altieri, NORML Communications Director May 17, 2014

    Earlier this week, the Drug Enforcement Administration ordered that 250 pounds of hemp seed be seized at Louisville Airport in Kentucky. The seeds were being imported by the Kentucky government from Italy to plant at state universities in their hemp pilot program. Kentucky legalized industrial hemp in 2013 and the federal government approved legislation this year that allowed states to engage in limited hemp cultivation.

    When the DEA refused to return the seeds under reasonable conditions, the Kentucky Agriculture Department filed suit against the Justice Department, the Drug Enforcement Administration, U.S. Customs and Border Protection and Attorney General Eric Holder.

    On Friday, there was a preliminary hearing regarding the lawsuit. During the hearing, U.S. District Judge John G. Heyburn II stated that the DEA must explicitly state what would need to be done for those participating in the pilot program to have the seeds returned. Federal officials responded that the Kentucky Department of Agriculture must fill out a narcotics license in addition to providing memorandum of agreement with the departments of universities planning to cultivate the crop.

    In an interview discussing the hearing with the Huffington Post, Kentucky Agriculture Commissioner James Comer stated, “It sounds like a victory, but I’m not going to declare victory until those seeds go in the ground. It was very positive today. But we’ve felt pretty good throughout this entire process over the last several weeks, and the DEA would come back and change again. I’m not celebrating. It will be a victory when I have those seeds in hand.”

    Elected officials across the state have voiced their support for the hemp program and decried the actions of federal officials. US Senate Minority Leader Mitch McConnell (R-KY) stated, “It is an outrage that DEA is using finite taxpayer dollars to impound legal industrial hemp seeds.”

    According to the Congressional Resource Service, the US is the only developed nation that fails to cultivate industrial hemp as an economic crop. However, in February, members of Congress for the first time approved language in the omnibus federal Farm Bill allowing for the cultivation of industrial hemp in agricultural pilot programs in states that already permit the growth and cultivation of the plant.

    The next court hearing is expected to occur on Wednesday, May 21. NORML will keep you updated as the situation evolves.

  • by Erik Altieri, NORML Communications Director May 16, 2014

    In the coming days, members of the House of Representatives are expected to debate and vote on budget appropriation legislation for the Department of Justice. Representatives Rohrabacher and Farr will be introducing an amendment to this measure to prevent any of the department’s funding from being used to interfere with medical marijuana programs in states that have approved them.

    Twenty-one states — Alaska, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, Nevada, Oregon, Rhode Island, Vermont, and Washington — as well as the District of Columbia have enacted laws protecting medical marijuana patients from state prosecution. Yet in all of these states, patients and providers still face the risk of federal sanction — even when their actions are fully compliant with state law.

    It is time that we allowed our unique federalist system to work the way it was intended. Patients, providers, and their state representatives should have the authority to enact laws permitting the medical use of cannabis — free from federal interference.

    Please write your members of Congress today and tell them to stop using taxpayer dollars to target and prosecute state-authorized medical marijuana patients and providers. For your convenience, a prewritten letter will be e-mailed to your member of Congress.

    CLICK HERE TO TAKE ACTION!

  • by Paul Armentano, NORML Deputy Director May 6, 2014

    Federal agencies are moving forward with plans to increase the US government’s production of research-grade cannabis.

    Last week, the US Drug Enforcement Administration (DEA) publicly announced in the Federal Register that it is increasing its marijuana production quota from 21 kilograms to 650 kilograms (about 1,443 pounds) in order to meet increasing demand for the plant from clinical investigators.

    Federal regulations permit a farm at the University of Mississippi to cultivate set quantities of cannabis for use in federally approved clinical trials. Regulators at the DEA, the US Food and Drug Administration, PHS (Public Health Service), and the US National Institute on Drug Abuse must approve any clinical protocol seeking to study the plant’s effects in human subjects.

    On various occasions, marijuana reform advocates and researchers have publicly criticized NIDA for failing to approve proposed trials seeking to assess the therapeutic benefits of cannabis. However, in March, federal regulators finally signed off on a long-delayed clinical protocol from researchers at the University of Arizona College of Medicine to evaluate the use of cannabis its in war veterans suffering from post-traumatic stress. Also this spring, lawmakers in several states, including Alabama, Kentucky, and Wisconsin, passed legislation encouraging state-sponsored clinical trials to assess the therapeutic potential of cannabidiol – a nonpsychotropic organic component of cannabis – in the treatment of intractable epilepsy.

    “The additional supply [of cannabis] to be manufactured in 2014 is designed to meet the current and anticipated research efforts involving marijuana,” A NIDA spokesperson told TheHill.com. “[T]his projection of increased demand is due in part to the recent increased interest in the possible therapeutic uses of marijuana.”

    According to a keyword search using the terms ‘smoked marijuana’ on the clinicaltrials.gov website, eight trials are presently ongoing to evaluate the plant’s effects in humans. Two of these trials are assessing the plant’s potential therapeutic efficacy.

Page 4 of 83« First...23456...102030...Last »